Cited by 2,051Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record.

Cancer Immunotherapy

Couzin-Frankel, Jennifer·2013·Science

Open this paper in CoChat — free account

Abstract

This year marks a turning point in cancer, as long-sought efforts to unleash the immune system against tumors are paying off—even if the future remains a question mark.

Integrity signals

Registry

Crossref · 10.1126/science.342.6165.1432

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 401–500 of 1,000

Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy
Kumar, A., Chamoto, K., Chowdhury, P. S., & Honjo, T. (2020) · eLife · doi:10.7554/elife.52330 · Cited by 64
Black phosphorus quantum dots doped multifunctional hydrogel particles for cancer immunotherapy
Shou, X., Liu, Y., Wu, D., Zhang, H., Zhao, Y., Sun, W., & Shen, X. (2020) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.127349 · Cited by 63
Role of Immune Cells and Receptors in Cancer Treatment: An Immunotherapeutic Approach
Mukherjee, A. G., Wanjari, U. R., Namachivayam, A., Murali, R., Prabakaran, D. S., Ganesan, R., Renu, K., Dey, A., Vellingiri, B., Ramanathan, G., et al. (2022) · Vaccines · doi:10.3390/vaccines10091493 · Cited by 69
Small-molecule agents for cancer immunotherapy
Wang, F., Fu, K., Wang, Y., Pan, C., Wang, X., Liu, Z., Yang, C., Zheng, Y. Y., Li, X., Lu, Y., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.12.010 · Cited by 71
Gut microbiome for predicting immune checkpoint blockade-associated adverse events
Hu, M., Lin, X., Sun, T., Shao, X., Huang, X., Du, W., Guo, M., Zhu, X., Zhou, Y., Tong, T., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01285-9 · Cited by 72
The immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma
Sheppard, S., Guedes, J., Mróz, A., Zavitsanou, A., Kudo, H., ROTHERY, S. M., Angelopoulos, P., Goldin, R. D., & Guerra, N. (2017) · Nature Communications · doi:10.1038/ncomms13930 · Cited by 64
Native Mass Spectrometry, Ion Mobility, and Collision-Induced Unfolding for Conformational Characterization of IgG4 Monoclonal Antibodies
Hernandez‐Alba, O., Wagner‐Rousset, E., Beck, A., & Cianférani, S. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b00912 · Cited by 64
Polyhydroxylated fullerenols regulate macrophage for cancer adoptive immunotherapy and greatly inhibit the tumor metastasis
Tang, J., Chen, Z., Sun, B., Dong, J., Liu, J., Zhou, H., Wang, L., Bai, R., Miao, Q., Zhao, Y., et al. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.11.021 · Cited by 63
Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants
Pestinger, V., Smith, M. R., Sillo, T., Findlay, J. M., Laes, J., Martin, G., Middleton, G., Taniere, P., & Beggs, A. D. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-020-00462-x · Cited by 62
Antitumor Activity and Potential Mechanism of Novel Fullerene Derivative Nanoparticles
Ye, L., Kollie, L., Liu, X., Guo, W., Ying, X., Zhu, J., Yang, S., & Yu, M. (2021) · Molecules · doi:10.3390/molecules26113252 · Cited by 63
Therapeutic cancer vaccines revamping: technology advancements and pitfalls
Antonarelli, G., Corti, C., Tarantino, P., Ascione, L., Cortés, J., Romero, P. J., Mittendorf, E., Disis, M. L., & Curigliano, G. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2153 · Cited by 64
Design of smart HPMA copolymer-based nanomedicines
Yang, J., & Kopec̆ek, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.003 · Cited by 63
Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients
Khoja, L., Kibiro, M., Metser, U., Gedye, C. A., Hogg, D., Butler, M. O., Atenafu, E. G., & Joshua, A. M. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.308 · Cited by 61
“The development of immune checkpoint inhibitors (ICIs) has heralded a new era in immuno-oncology (Couzin-Frankel, 2013).”
Background
Upregulation of T-cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Monocytes/Macrophages Associates with Gastric Cancer Progression
Wang, Z., Yin, N., Zhang, Z., Zhang, Y., Zhang, G., & Chen, W. (2016) · Immunological Investigations · doi:10.1080/08820139.2016.1229790 · Cited by 65
Therapeutic Implications of Autophagy Inducers in Immunological Disorders, Infection, and Cancer
Byun, S., Lee, E., & Lee, K. W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091959 · Cited by 64
“Recently, the activation of host immunity to treat cancer has been recognized as one of the most promising novel therapeutic approaches [43].”
Background
A Bayesian Phase I/II Trial Design for Immunotherapy
Liu, S., Guo, B., & Yuan, Y. (2017) · Journal of the American Statistical Association · doi:10.1080/01621459.2017.1383260 · Cited by 63
“…that harness and enhance the innate power of the immune system to fight cancer— represents the most promising new cancer treatment approach since the first chemotherapies were developed in the late 1940’s (Topalian, Weiner, and Pardoll 2011; Couzin-Frankel 2013; Makkouk and Weiner 2015).”
Background
Recent advances in mass spectrometry-based approaches for proteomics and biologics: Great contribution for developing therapeutic antibodies
Iwamoto, N., & Shimada, T. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.007 · Cited by 68
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
Cuesta‐Mateos, C., Alcaraz‐Serna, A., Somovilla-Crespo, B., & Muñoz‐Calleja, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01936 · Cited by 65
“” Although checkpoint targeting with specific antibodies is a relatively new area (346), their accessibility to cell membranes and significance in regulating immune responses made them a very attractive therapy option, as exemplified by the plethora of novel agents that have been already approved or are under intensiv…”
Background
PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer
Morihiro, T., Kuroda, S., Kanaya, N., Kakiuchi, Y., Kubota, T., Aoyama, K., Tanaka, T., Kikuchi, S., Nagasaka, T., Nishizaki, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41177-2 · Cited by 64
Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients
Snook, A. E., Baybutt, T. R., Xiang, B., Abraham, T. S., Flickinger, J. C., Hyslop, T., Zhan, T., Kraft, W. K., Sato, T., & Waldman, S. A. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0576-2 · Cited by 62
Tumor-infiltrating lymphocytes: Streamlining a complex manufacturing process
Hopewell, E. L., Cox, C. A., Pilon‐Thomas, S., et al. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2018.11.004 · Cited by 62
Tumor-targeted nanoplatform for in situ oxygenation-boosted immunogenic phototherapy of colorectal cancer
He, H., Liu, L., Liang, R., Zhou, H., Pan, H., Zhang, S., & Cai, L. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.01.012 · Cited by 63
Recent advances in breast cancer immunotherapy: The promising impact of nanomedicines
Hashemzadeh, N., Dolatkhah, M., Adibkia, K., Aghanejad, A., Barzegar-Jalali, M., Omidi, Y., & Barar, J. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119110 · Cited by 64
Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity
Heemskerk, N., Gruijs, M., Temming, A. R., Heineke, M. H., Gout, D. Y., Hellingman, T., Tuk, C. W., Winter, P. J., Lissenberg‐Thunnissen, S. N., Bentlage, A. E. H., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci134680 · Cited by 64
Post-transplantation malignancies: here today, gone tomorrow?
Geissler, E. K. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.186 · Cited by 63
PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes
He, Y., Rozeboom, L. M., Rivard, C. J., Ellison, K. E., Dziadziuszko, R., Yu, H., Zhou, C., & Hirsch, F. R. (2017) · Medical Science Monitor · doi:10.12659/msm.899909 · Cited by 61
[18F]tetrafluoroborate-PET/CT enables sensitive tumor and metastasis in vivo imaging in a sodium iodide symporter-expressing tumor model
Diocou, S., Volpe, A., Jauregui-Osoro, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01044-4 · Cited by 62
Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma
Sadozai, H., Gruber, T., Hunger, R. E., & Schenk, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01617 · Cited by 62
Recent success and limitations of immune checkpoint inhibitors for cancer: A lesson from melanoma
Ottaviano, M., De Placido, S., & Ascierto, P. A. (2019) · Virchows Archiv · doi:10.1007/s00428-019-02538-4 · Cited by 57
A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy
Sasikumar, P. G., Ramachandra, R. K., Adurthi, S., Dhudashiya, A. A., Vadlamani, S., Vemula, K., Vunnum, S., Satyam, L. K., Samiulla, D. S., Subbarao, K., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0737 · Cited by 62
Challenges and Opportunities in Dose Finding in Oncology and Immuno‐oncology
Ji, Y., Jin, J. Y., Hyman, D. M., et al. (2018) · Clinical and Translational Science · doi:10.1111/cts.12540 · Cited by 61
Reducing the Cytotoxicity of Lipid Nanoparticles Associated with a Fusogenic Cationic Lipid in a Natural Killer Cell Line by Introducing a Polycation-Based siRNA Core
Nakamura, T., Yamada, K., Fujiwara, Y., Sato, Y., & Harashima, H. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b01166 · Cited by 60
Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET–CT
Dimitrakopoulou‐Strauss, A. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2229-6 · Cited by 61
The antigen‐binding moiety in the driver's seat of CARs
Hanssens, H., Meeus, F., Veirman, K. D., Breckpot, K., & Devoogdt, N. (2021) · Medicinal Research Reviews · doi:10.1002/med.21818 · Cited by 63
Fenton metal nanomedicines for imaging-guided combinatorial chemodynamic therapy against cancer
Liu, P., Peng, Y., Ding, J., & Zhou, W. (2021) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2021.10.003 · Cited by 60
Engineered Probiotic‐Based Personalized Cancer Vaccine Potentiates Antitumor Immunity through Initiating Trained Immunity
Chen, Z., Yong, T., Wei, Z., Zhang, X., Li, X., Qin, J., Li, J., Hu, J., Yang, X., & Gan, L. (2023) · Advanced Science · doi:10.1002/advs.202305081 · Cited by 61
Desmoplastic Small Round Cell Tumor 20 Years After its Discovery
Mora, J., Modak, S. I., Cheung, N. V., Meyers, P. A., de Álava, E., Kushner, B. H., Magnan, H., Tirado, Ò. M., LaQuaglia, M. P., Ladanyi, M., et al. (2015) · Future Oncology · doi:10.2217/fon.15.32 · Cited by 60
A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice
Liu, Z., Zhou, H., Wang, W., Fu, Y., & Zhu, M. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1147641 · Cited by 60
“of this signaling pathway has recently shown impressive effects in cancer immunotherapy.(36-41) However, whether and”
Background
Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches
Kamta, J., Chaar, M., Ande, A., Altomare, D. A., & Ait‐Oudhia, S. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00064 · Cited by 61
Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy
Weng, T., Qiu, X., Wang, J., Li, Z., & Bian, J. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.088 · Cited by 63
Modeling Immunity In Vitro: Slices, Chips, and Engineered Tissues
Hammel, J. H., Cook, S. R., Belanger, M. C., Munson, J. M., & Pompano, R. R. (2021) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-082420-124920 · Cited by 60
Silk Embolic Material for Catheter‐Directed Endovascular Drug Delivery
Hu, J., Albadawi, H., Zhang, Z., Salomao, M. A., Gunduz, S. G., Rehman, S., d’Amone, L., Mayer, J. L., Omenetto, F. G., & Öklü, R. (2021) · Advanced Materials · doi:10.1002/adma.202106865 · Cited by 59
Prognostic Value of Lymphocyte Activation Gene-3 (LAG-3) Expression in Esophageal Squamous Cell Carcinoma
Zhang, Y., Liu, Y.-D., Luo, Y., et al. (2018) · Journal of Cancer · doi:10.7150/jca.26949 · Cited by 59
Rational Design of Potent Peptide Inhibitors of the PD-1:PD-L1 Interaction for Cancer Immunotherapy
Yin, H., Zhou, X., Huang, Y.-H., King, G. J., Collins, B. M., Gao, Y., Craik, D. J., & Wang, C. K. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c08132 · Cited by 57
Genomics and the Immune Landscape of Osteosarcoma
Wu, C.-C., & Livingston, J. A. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-43085-6_2 · Cited by 58
Mitochondria-Targeted Nanomedicine for Enhanced Efficacy of Cancer Therapy
Gao, Y. F., Tong, H., Li, J., Li, J., Huang, D., Shi, J., & Xia, B. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.720508 · Cited by 61
“In novel cancer therapy modalities, cancer immunotherapy represents the most innovative approach (Couzin-Frankel, 2013).”
Background
Immunogenic Cell Death and Role of Nanomaterials Serving as Therapeutic Vaccine for Personalized Cancer Immunotherapy
Catanzaro, E., Féron, O., Skirtach, A. G., & Krysko, D. V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.925290 · Cited by 62
Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors
Foster, J., Griffin, C., Rokita, J. L., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004450 · Cited by 58
Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.
Godakhindi, V., Tarannum, M., Dam, S. K., & Vivero-Escoto, J. L. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400323 · Cited by 65
Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma
Ritter, C., Fan, K., Paulson, K. G., et al. (2016) · Scientific Reports · doi:10.1038/srep21678 · Cited by 58
Immunochemotherapy mediated by thermosponge nanoparticles for synergistic anti-tumor effects
Zhao, Y., Song, Q., Yin, Y., Wu, T., Hu, X., Gao, X., Gao, L., Tan, S., & Zhang, Z. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.037 · Cited by 58
Obesity and CD8 T cell metabolism: Implications for anti‐tumor immunity and cancer immunotherapy outcomes
Turbitt, W. J., Rosean, C. B., Weber, K. S., & Norian, L. A. (2020) · Immunological Reviews · doi:10.1111/imr.12849 · Cited by 61
Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma
Fröhlich, A., Sirokay, J. D., Fietz, S., Vogt, T. J., Dietrich, J., Zarbl, R., Florin, M., Kuster, P., Saavedra, G., Valladolid, S. R., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102962 · Cited by 61
In Situ-Induced Multivalent Anticancer Drug Clusters in Cancer Cells for Enhancing Drug Efficacy
Zhou, L., Lv, F., Liu, L., et al. (2019) · CCS Chemistry · doi:10.31635/ccschem.019.20180015 · Cited by 57
Tumor associated macrophages reprogrammed by targeted bifunctional bioorthogonal nanozymes for enhanced tumor immunotherapy
Yue, W., Wu, S., Liu, Z., Niu, J., Zhou, Y., Ren, J., & Qu, X. (2022) · Materials Today · doi:10.1016/j.mattod.2022.01.024 · Cited by 57
Visualizing vasculature and its response to therapy in the tumor microenvironment
Lin, Q., Choyke, P. L., & Sato, N. (2023) · Theranostics · doi:10.7150/thno.84947 · Cited by 68
“Cancer immunotherapy has revolutionized cancer treatment and was named the 2013 “Breakthrough of the Year” by the journal Science [172].”
Background
Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies
Dai, M., Yip, Y. Y., Hellström, I., & Hellström, K. E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1339 · Cited by 61
IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class I–Deficient Tumors
Seo, H., Kim, B. S., Bae, E., Min, B. S., Han, Y. D., Shin, S. J., & Kang, C. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0708 · Cited by 59
Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival
Markowitz, G. J., Havel, L. S., Crowley, M. J. P., Ban, Y., Lee, S. B., Thalappillil, J. S., Narula, N., Bhinder, B., Elemento, O., Wong, S. T. C., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96836 · Cited by 59
“Our data indicate that in early-stage NSCLC T lymphocytes exhibit cell type–specific functional cytokine production and differential gene expression upon therapy-induced tumor regression (Figures 5 and 8).”
Background
T Cell-Redirecting Strategies to ‘STAb’ Tumors: Beyond CARs and Bispecific Antibodies
Blanco, B., Compte, M., Lykkemark, S., Sanz, L., & Álvarez‐Vallina, L. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.01.008 · Cited by 59
Fabrication of H 2 O 2 -driven nanoreactors for innovative cancer treatments
Dong, Z., Yang, Z., Hao, Y., & Feng, L. (2019) · Nanoscale · doi:10.1039/c9nr04418c · Cited by 56
Tuning the size, shape and structure of RNA nanoparticles for favorable cancer targeting and immunostimulation
Guo, S., Xu, C., Yin, H., Hill, J. L., Pi, F., & Guo, P. (2019) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1582 · Cited by 57
“One of the most important recent breakthroughs in cancer research is cancer immunotherapy (Couzin-Frankel, 2013; McNutt, 2013).”
Background
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer
Trüb, M., Uhlenbrock, F., Claus, C., Herzig, P., Thelen, M., Karanikas, V., Bacac, M., Amann, M., Albrecht, R., Ferrara, C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000238 · Cited by 58
Synergistic Effect of Photothermally Targeted NIR-Responsive Nanomedicine-Induced Immunogenic Cell Death for Effective Triple Negative Breast Cancer Therapy
Yasothamani, V., Karthikeyan, L., Shyamsivappan, S., Haldorai, Y., Dayakar, S., & Vivek, R. (2021) · Biomacromolecules · doi:10.1021/acs.biomac.1c00244 · Cited by 58
Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert
Li, X., Gulati, M., Larson, A. C., Solheim, J. C., Jain, M., Sushil Kumar, K., & Batra, S. K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.009 · Cited by 56
Recent advances and clinical challenges of phototherapeutic nanoparticles in cancer monotherapy or combination therapy
Zhang, Y., Zhang, Y., Zhang, G., Wu, J., Wang, L., Dong, Z., Zheng, Y., Huang, Q., Zou, M., Liao, R., et al. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216069 · Cited by 57
“Glowing Head” Mice: A Genetic Tool Enabling Reliable Preclinical Image-Based Evaluation of Cancers in Immunocompetent Allografts
Day, C., Carter, J., Ohler, Z. W., Bonomi, C., Meskini, R. E., Martin, P., Graff‐Cherry, C., Feigenbaum, L., Tüting, T., Dyke, T. V., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109956 · Cited by 56
Predictive role of toll-like receptors 2, 4, and 9 in oral tongue squamous cell carcinoma
Mäkinen, L. K., Atula, T. S., Häyry, V., et al. (2014) · Oral Oncology · doi:10.1016/j.oraloncology.2014.08.017 · Cited by 56
“Cancer immunotherapy is expected to be the fourth weapon against cancer along with surgery, radiation, and chemotherapy [4].”
Background
NF-κB RelA renders tumor-associated macrophages resistant to and capable of directly suppressing CD8 + T cells for tumor promotion
Li, L., Han, L., Sun, F., Zhou, J., Ohaegbulam, K. C., Tang, X.-D., Zang, X., Steinbrecher, K. A., Qu, Z., & Xiao, G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1435250 · Cited by 55
Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors
Reul, J., Frisch, J., Engeland, C. E., Thalheimer, F. B., Hartmann, J., Ungerechts, G., & Buchholz, C. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00052 · Cited by 56
“In fact, cancer immunotherapy has been celebrated as breakthrough technology of the year 2013 due to substantial benefit observed in clinical trials (1).”
Background
A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity
Das, K., Belnoue, E., Rossi, M., Hofer, T., Danklmaier, S., Nolden, T., Schreiber, L.-M., Angerer, K., Kimpel, J., Hoegler, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25506-6 · Cited by 55
Rapid assessment of T-cell receptor specificity of the immune repertoire
Lin, X., George, J. T., Schafer, N. P., Chau, K. N., Birnbaum, M. E., Clementi, C., Onuchic, J. N., & Levine, H. (2021) · Nature Computational Science · doi:10.1038/s43588-021-00076-1 · Cited by 56
“The advent of new strategies that unleash the host immune system to battle malignant cells represents 42 one of the largest paradigm shifts in treating cancer and has ushered in a new frontier of cancer 43 immunotherapy [1].”
Background
iTTCA-RF: a random forest predictor for tumor T cell antigens
Jiao, S., Zou, Q., Guo, H., & Shi, L. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03084-x · Cited by 57
Immunogenic hydrogel toolkit disturbing residual tumor “seeds” and pre-metastatic “soil” for inhibition of postoperative tumor recurrence and metastasis
Zhou, M., Zuo, Q., Huang, Y., & Li, L. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.017 · Cited by 59
“P-DOX, fluorescein 5(6)-isothiocyanate FITC labeled P-(LV)6 or cyanine 5 (Cy5) labeled mAb were loaded in the hydrogels for detection.”
Method
Neutrophils as immune effector cells in antibody therapy in cancer
Behrens, L. M., van Egmond, M., & van den Berg, T. K. (2022) · Immunological Reviews · doi:10.1111/imr.13159 · Cited by 62
Peptide Hydrogels as Immunomaterials and Their Use in Cancer Immunotherapy Delivery
Falcone, N., Ermis, M., Tamay, D. G., Mecwan, M. M., Monirizad, M., Mathes, T. G., Jucaud, V., Choroomi, A., de Barros, N. R., Zhu, Y., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301096 · Cited by 60
Non‐coding RNAs in cancer immunotherapy: Predictive biomarkers and targets
Alahdal, M., & Elkord, E. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1425 · Cited by 55
Microbiome bacterial influencers of host immunity and response to immunotherapy
Yousefi, Y., Baines, K. J., & Vareki, S. M. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101487 · Cited by 60
“33,34 Immune checkpoint inhibitors (ICIs) are among immunotherapy approaches that block immune inhibitory molecules on T cells.”
Background
Long-term intravital imaging of the multicolor-coded tumor microenvironment during combination immunotherapy
Qi, S., Li, H., Lu, L., Qi, Z., Liu, L., Chen, L., Shen, G., Fu, L., Luo, Q., & Zhang, Z. (2016) · eLife · doi:10.7554/elife.14756 · Cited by 56
“Cancer immunotherapy has been an area of significant process in recent decades, and is considered a breakthrough in cancer therapy (Couzin-Frankel, 2013).”
Background
Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors
Jardim, D. L. F., Gagliato, D. D. M., Giles, F. J., & Kurzrock, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1970 · Cited by 54
“as the science breakthrough of 2013 (11).”
Modestly weighted logrank tests
Magirr, D., & Burman, C. (2019) · Statistics in Medicine · doi:10.1002/sim.8186 · Cited by 55
LAG-3 expression on tumor-infiltrating T cells in soft tissue sarcoma correlates with poor survival
Que, Y., Zhixin, F., Guan, Y., Wei, X., Bushu, X., Jingjing, Z., Huoying, C., Xinke, Z., Zeng, M., Yao, L., et al. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0306 · Cited by 55
Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence
Zhou, X., Qu, M., Tebon, P. J., Jiang, X., Wang, C., Xue, Y., Zhu, J., Zhang, S., Öklü, R., Sengupta, S., et al. (2020) · Advanced Science · doi:10.1002/advs.202001447 · Cited by 55
Bacterial outer membrane vesicle-based cancer nanovaccines
Gao, X., Feng, Q., Wang, J., & Zhao, X. (2022) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0452 · Cited by 56
Extracellular Vesicles and Their Roles in the Tumor Immune Microenvironment
Reale, A., Khong, T. T., & Spencer, A. G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11236892 · Cited by 57
Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies
Mick, R., & Chen, T. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0260 · Cited by 50
“The past several years have witnessed a revival of interest in cancer immunology and immunotherapy owing to striking immunologic and clinical responses to immune-directed anticancer therapies and leading to the selection of "Cancer Immunotherapy" as the 2013 Breakthrough of the Year by Science.”
Background
Bispecific antibodies in cancer immunotherapy
Chen, S., Li, J., Li, Q., & Wang, Z. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1187802 · Cited by 55
“nesses the body’s immune system to fight cancer, was named “2013’s Breakthrough of the Year” by Science.(2) The promise of”
Background
Tuning cancer fate: the unremitting role of host immunity
Calì, B., Molon, B., & Viola, A. (2017) · Open Biology · doi:10.1098/rsob.170006 · Cited by 58
Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs
Dranitsaris, G., Zhu, X., Adunlin, G., & Vincent, M. D. (2018) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2018.1467270 · Cited by 53
Updates in Melanoma
Tracey, E. H., & Vij, A. (2018) · Dermatologic Clinics · doi:10.1016/j.det.2018.08.003 · Cited by 54
Ubiquitin Ligases in Cancer Immunotherapy – Balancing Antitumor and Autoimmunity
Fujita, Y., Tinoco, R., Li, Y., Senft, D., & Ronai, Z. A. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.02.002 · Cited by 55
Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients
Omura, Y., Toiyama, Y., Okugawa, Y., Yin, C., Shigemori, T., Kusunoki, K., Kusunoki, Y., Ide, S., Shimura, T., Fujikawa, H., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02645-1 · Cited by 56
Exploring the Modulatory Effects of Gut Microbiota in Anti-Cancer Therapy
Li, W., Deng, X., & Chen, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.644454 · Cited by 55
“It targets cancer cells with the aid of host immune system, and has already proved to be effective in many clinical trials (42).”
Background
A Roadmap Toward the Definition of Actionable Tumor-Specific Antigens
Minati, R., Perreault, C., & Thibault, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583287 · Cited by 55
STING agonist-loaded mesoporous manganese-silica nanoparticles for vaccine applications
Xu, C., Dobson, H. E., Yu, M., Gong, W., Sun, X., Park, K. S., Kennedy, A., Zhou, X., Xu, J., Xu, Y., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.03.036 · Cited by 53
“Promising achievements have been made in the field of cancer immunotherapy, including the development of immune checkpoint blockade therapy and tumor neoantigen-based cancer vaccines [1,2].”
microRNA-155 deficiency impairs dendritic cell function in breast cancer
Wang, J., Iwanowycz, S., Yu, F., Jia, X., Leng, S., Wang, Y., Li, W., Huang, S., Ai, W., & Fan, D. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1232223 · Cited by 54
“Immunotherapies are becoming mainstay therapies for several types of cancer.(1) Although passive immunotherapies, best represented by T-cell immunomodulatory monoclonal antibodies”
Background
An FDA oncology analysis of immune activating products and first-in-human dose selection
Saber, H., Gudi, R., Manning, M. L., Wearne, E., & Leighton, J. K. (2016) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2016.10.002 · Cited by 53
Current and upcoming mitochondrial targets for cancer therapy
Kim, H. K., Noh, Y. H., Nilius, B., Ko, K. S., Rhee, B. D., Kim, N., & Han, J. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.06.006 · Cited by 52
Improved survival of chimeric antigen receptor‐engineered T ( CAR ‐T) and tumor‐specific T cells caused by anti‐programmed cell death protein 1 single‐chain variable fragment‐producing CAR ‐T cells
Nakajima, M., Sakoda, Y., Adachi, K., Nagano, H., & Tamada, K. (2019) · Cancer Science · doi:10.1111/cas.14169 · Cited by 53
Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold
Qin, M., Cao, Q., Wu, X., Liu, C., Zheng, S., Xie, H., Tian, Y., Xie, J., Zhao, Y., Hou, Y., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111856 · Cited by 59

Authors: Couzin-Frankel, J.
Corresponding author: Couzin-Frankel, Jennifer
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2013-12-20
Volume: 342
Issue: 6165
Pages: 1432-1433
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.342.6165.1432
OpenAlex: W2209812019
Cited by: 2,051
References: 0
Citations by year: 2026: 34 · 2025: 100 · 2024: 133 · 2023: 154 · 2022: 172 · 2021: 215 · 2020: 220 · 2019: 197 · 2018: 206 · 2017: 206 · 2016: 138 · 2015: 169 · 2014: 103 · 2013: 2
FWCI: 73.49
Type: journal article
Language: en
Open access: closed
Locations: Science (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: cancer immunotherapy, tumor immunology, immune checkpoint inhibitors
MeSH terms: Ipilimumab, Antibodies, Antibodies, Monoclonal, Clinical Trials as Topic, Humans, Immunotherapy, Melanoma, Neoplasms, T-Lymphocytes, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cancer Immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks